Rating scales as outcome measures for clinical trials in neurology: problems, solutions, and recommendations

被引:364
|
作者
Hobart, Jeremy C. [1 ,2 ]
Cano, Stefan J. [2 ]
Zajicek, John P.
Thompson, Alan J. [2 ]
机构
[1] Peninsula Coll Med & Dent, Neurol Outcome Measures Unit, Plymouth PL6 8BX, Devon, England
[2] UCL Inst Neurol, London WC1N 3BG, England
来源
LANCET NEUROLOGY | 2007年 / 6卷 / 12期
关键词
D O I
10.1016/S1474-4422(07)70290-9
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Have state-of-the-art clinical trials failed to deliver treatments for neurodegenerative diseases because of shortcomings in the rating scales used? This Review assesses two methodological limitations of rating scales that might help to answer this question. First, the numbers generated by most rating scales do not satisfy the criteria for rigorous measurements. Second, we do not really know which variables most rating scales measure. We use clinical examples to highlight concerns about the limitations of rating scales, examine their underlying rationales, clarify their implications, explore potential solutions, and make some recommendations for future research. We show that improvements in the scientific rigour of rating scales can improve the chances of reaching the correct conclusions about the effectiveness of treatments.
引用
收藏
页码:1094 / 1105
页数:12
相关论文
共 50 条
  • [21] Is There a Relationship between Clinical Rating Scales and Instrumental Gait Stability Measures?
    Riva, Federico
    Tamburini, Paola
    Mazzoli, Davide
    Stagni, Rita
    [J]. 6TH EUROPEAN CONFERENCE OF THE INTERNATIONAL FEDERATION FOR MEDICAL AND BIOLOGICAL ENGINEERING, 2015, 45 : 360 - +
  • [22] A commentary on the use of depression rating scales in clinical trials conducted in India
    Kuruvilla, P. K.
    Chandran, Hari S.
    Chengappa, K. N. R.
    [J]. ASIAN JOURNAL OF PSYCHIATRY, 2009, 2 (01) : 3 - 5
  • [23] Outcome measures in multiple sclerosis clinical trials
    Andersson, PB
    Goodkin, DE
    [J]. BAILLIERES CLINICAL NEUROLOGY, 1997, 6 (03): : 409 - 428
  • [24] Outcome Measures for Clinical Trials in Down Syndrome
    Esbensen, Anna J.
    Hooper, Stephen R.
    Fidler, Deborah
    Hartley, Sigan L.
    Edgin, Jamie
    d'Ardhuy, Xavier Liogier
    Capone, George
    Conners, Frances A.
    Mervis, Carolyn B.
    Abbeduto, Leonard
    Rafii, Michael
    Krinsky-McHale, Sharon J.
    Urv, Tiina
    [J]. AJIDD-AMERICAN JOURNAL ON INTELLECTUAL AND DEVELOPMENTAL DISABILITIES, 2017, 122 (03): : 247 - 281
  • [25] OUTCOME MEASURES FOR CLINICAL-TRIALS IN RHEUMATOLOGY
    TUGWELL, P
    BUCHANAN, W
    BOMBARDIER, C
    [J]. EUROPEAN JOURNAL OF RHEUMATOLOGY AND INFLAMMATION, 1983, 6 (02) : 140 - 141
  • [26] Outcome measures for clinical drug trials in autism
    Aman, MG
    Novotny, S
    Samango-Sprouse, C
    Lecavalier, L
    Leonard, E
    Gadow, KD
    King, BH
    Pearson, DA
    Gernsbacher, MA
    Chez, M
    [J]. CNS SPECTRUMS, 2004, 9 (01) : 36 - 47
  • [27] Outcome Measures in Clinical Trials for Multiple Sclerosis
    Caspar E. P. van Munster
    Bernard M. J. Uitdehaag
    [J]. CNS Drugs, 2017, 31 : 217 - 236
  • [28] Outcome Measures in Clinical Trials for Multiple Sclerosis
    van Munster, Caspar E. P.
    Uitdehaag, Bernard M. J.
    [J]. CNS DRUGS, 2017, 31 (03) : 217 - 236
  • [29] Clinical outcome measures for progressive MS trials
    Ontaneda, Daniel
    Cohen, Jeffrey A.
    Amato, Maria Pia
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2017, 23 (12) : 1627 - 1635
  • [30] STATISTICAL QUESTION Clinical trials: outcome measures
    Sedgwick, Philip
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 2015, 350